Septerna Inc

SEPN

Healthcare|Biotechnology|USA

$35.93

-1.91 (-5.05%)

Tangible Book

$8.43

About

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Stock Price

+207.6%(1Y)

Pipeline Summary

2 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 1Completed: 1

Active Trials (1)

A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants

NCT07433179Healthy Volunteers

Phase 1Recruiting

Enrollment: 150 participants

BioScore

4.4/10

Cautious

Ownership

Recent Insider Trades

Long Daniel D.SELL

2026-07-013,333 shares @ $34.36

Shaikhly SamiraSELL

2026-06-292,178 shares @ $35.18

Long Daniel D.SELL

2026-06-2215,000 shares @ $35.51

Shaikhly SamiraSELL

2026-06-126,250 shares @ $35.08

Shaikhly SamiraSELL

2026-06-015,935 shares @ $28.93

Recent News

2026-07-01 13:38:41

2026-07-01 12:44:23

2026-07-01 12:38:07

2026-06-27 02:00:04

Data last updated: Jul 13, 2026, 12:46 PM